354 related articles for article (PubMed ID: 29436077)
1. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW
Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077
[TBL] [Abstract][Full Text] [Related]
2. Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.
Meeks SL; Lacroix-Desmazes S
Haemophilia; 2020 Nov; 26(6):958-965. PubMed ID: 32885562
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.
Nolan B; Mahlangu J; Pabinger I; Young G; Konkle BA; Barnes C; Nogami K; Santagostino E; Pasi KJ; Khoo L; Winding B; Yuan H; Fruebis J; Rudin D; Oldenburg J
Haemophilia; 2020 May; 26(3):494-502. PubMed ID: 32227570
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII-Fc Activates Natural Killer Cells
Lagassé HAD; Hopkins LB; Jankowski W; Jacquemin MG; Sauna ZE; Golding B
Front Immunol; 2021; 12():692157. PubMed ID: 34262568
[TBL] [Abstract][Full Text] [Related]
6. rFVIIIFC for hemophilia A prophylaxis.
Mahlangu J
Expert Rev Hematol; 2018 Dec; 11(12):937-943. PubMed ID: 30449223
[No Abstract] [Full Text] [Related]
7. Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A.
Ebbert PT; Xavier F; Malec LM; Seaman CD; Ragni MV
Thromb Res; 2020 Nov; 195():51-54. PubMed ID: 32653601
[TBL] [Abstract][Full Text] [Related]
8. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
Lorenzoni V; Triulzi I; Turchetti G
BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIII Fc for the treatment of haemophilia A.
Hermans C; Mancuso ME; Nolan B; Pasi KJ
Eur J Haematol; 2021 Jun; 106(6):745-761. PubMed ID: 33650192
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
[TBL] [Abstract][Full Text] [Related]
11. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
[TBL] [Abstract][Full Text] [Related]
12. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study.
Rivard GE; Rothschild C; Toll T; Achilles K
Haemophilia; 2013 May; 19(3):449-55. PubMed ID: 23510123
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.
Kis-Toth K; Rajani GM; Simpson A; Henry KL; Dumont J; Peters RT; Salas J; Loh C
Blood Adv; 2018 Nov; 2(21):2904-2916. PubMed ID: 30396910
[TBL] [Abstract][Full Text] [Related]
14. Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.
Robertson JD; Higgins P; Price J; Dunkley S; Barrese G; Curtin J
Thromb Res; 2014 Nov; 134(5):1046-51. PubMed ID: 25267706
[TBL] [Abstract][Full Text] [Related]
15. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
[TBL] [Abstract][Full Text] [Related]
16. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein.
Oldenburg J; Kulkarni R; Srivastava A; Mahlangu JN; Blanchette VS; Tsao E; Winding B; Dumont J; Jain N
Haemophilia; 2018 Jan; 24(1):77-84. PubMed ID: 29082639
[TBL] [Abstract][Full Text] [Related]
17. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
Mahlangu JN; Ragni M; Gupta N; Rangarajan S; Klamroth R; Oldenburg J; Nogami K; Young G; Cristiano LM; Dong Y; Allen G; Pierce GF; Robinson B
Thromb Haemost; 2016 Jul; 116(1):1-8. PubMed ID: 26962852
[TBL] [Abstract][Full Text] [Related]
18. Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery.
Désage S; Nougier C; Meunier S; Chamouard V; Jousselme E; Dargaud Y; Lienhart A
Haemophilia; 2024 Mar; 30(2):538-544. PubMed ID: 38149726
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
[TBL] [Abstract][Full Text] [Related]
20. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors.
Kurth MA; Dimichele D; Sexauer C; Sanders JM; Torres M; Zappa SC; Ragni M; Leonard N
Haemophilia; 2008 Jan; 14(1):50-5. PubMed ID: 17941829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
